^
    Back
    Association details:
    Biomarker:RAS mutation
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

    Excerpt:
    ...RAS gene mutation, BRAF wild-type and microsatellite stable confirmed by polymerase chain reaction using a panel of six mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, NR-27, and MONO-27); 4....
    Trial ID:
    BBCAPX-II
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EClinicalMedicine
    Title:

    Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

    Published date:
    07/27/2023
    Excerpt:
    Two (8%) patients showed complete response (CR), 19 (76%) had partial response (PR) and 4 (16%) presented with stable disease. ORR reached 84% (95% CI, 63.9–95.5) and the disease control rate was 100% (95% CI, 86.3–100). The median progression-free survival (PFS) was 18.2 months for the full analysis set...Combination treatment with sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line treatment demonstrated a promising antitumor activity and a manageable safety profile in RAS-mutant, MSS and unresectable mCRC.
    Secondary therapy:
    capecitabine + oxaliplatin
    DOI:
    https://doi.org/10.1016/j.eclinm.2023.102123
    Trial ID:
    BBCAPX-II
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

    Published date:
    05/25/2023
    Excerpt:
    Objective response rate (ORR) reached 84.0% and disease control rate was 100.0%. The median PFS was 18.2 months for the full analysis set….Combination treatment of sintilimab plus bevacizumab and CapeOX as first-line treatment demonstrated a high ORR (84.0%) and a manageable safety profile in RAS-mutant, MSS unresectable mCRC.
    Secondary therapy:
    CAPOX
    DOI:
    10.1200/JCO.2023.41.16_suppl.2606
    Trial ID:
    NCT05171660